Ann: Final Report and Annual Report to Shareholders, page-8

That people are selling here ahead of the ATI release, and after the Striate deal is, well I'd like to say crazy, but the small cap end of town is crazy. Some stupid price behaviour in bio-techs since EOFY and money to be made for the brave. Anderson must be scratching his head on the share price...."A top 5 global dental pharma partnership....what do I have to do?".

There is a good bit of detail in the notes on the BH deal. The manufacturing facilities present upgrades for the deal are finished at 100,000 as of August. Should certainly see decent sales in Striate emerge in the 4Q (2022 CY). Lets hope some of the skepticism on OCC's Striate unit sales prices answered soon.